OVARIAN STIMULATION FOR IVF-ET PROCEDURE
Abstract
Background. It is well known that the efficiency of fertilization in vitro depends on the number of transferred embryos. To provide the conditions for the development of a higher number of ovarian follicles, from which a higher number of oocytes can be obtained, various regimens of ovarian stimulation have been used. Ovulation stimulation in in vitro fertilization – embryo transfer (IVF-ET) is performed by gonadotropins alone, by a combination of gonadotropins plus gonadotropin-releasing hormone (GnRH) agonists or by a combination of gonadotropins plus GnRH antagonists. The use of gonadotropins alone is being abandoned. In most centres involved in the treatment of infertility and IVF procedures, the combination of gonadotropins and GnRH agonists is the most frequent regimen used for ovarian stimulation, whereas GnRH antagonists are in the phase of being introduced in the routine clinical work.
Conclusions. At the Department of Obstetrics and Gynecology in Ljubljana, ovarian stimulation with gonadotropins alone was abandoned at the end of 2000. In all the patients treated at our centre ovarian stimulation is currently done using the combination of gonadotropins and GnRH agonists, since the results are much better. Further clinical research will elucidate the possibilities offered by GnRH antagonists introduced in routine clinical work.
Downloads
References
Meden-Vrtovec H, Hren-Vencelj H. Zunajtelesna oploditev. In: MedenVrtovec H ed. Neplodnost. Ljubljana: Cankarjeva založba, 1989: 343–62.
Virant-Klun I, Veble A, Valenčič B et al. Zamrzovanje in odmrzovanje zarodkov v programu zunajtelesne oploditve. Zdrav Vestn 1998; 67: 495–9.
Stanger JD, Yovich JL. Reduced in vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. Br J Obstet Gynaecol 1985; 92: 385–92.
Homburg R, Armar NA, Eshel A et al. Influence of serum luteinizing hormone concentrations on ovulation, conception and early pregnancy loss in polycystic ovarian syndrome. Br Med J 1988; 297: 1024–6.
Punnonen R, Ashorn R, Vilja P et al. Spontaneous luteinizing hormone surge and cleavage of in vitro fertilized embryos. Fertil Steril 1988; 49: 479–82.
Daya S, Gunby J, Hughes EG et al. Follicle-stimulating hormone versus human menopausal gonadotrophin for in vitro fertilization cycles: a metaanalysis. Fertil Steril 1995; 64: 77–86.
Howles CM, Loumaye E, Giroud D, Luyed G. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation (Metrodin High Purity) in pituitary desensitized women undergoing IVF-ET: a multicentre European Phase III study. Hum Reprod 1994; 9: 424–30.
Wikland M, Borg J, Hamberger L, Sulander P. Simplification of IVF, minimal monitoring and the use of subcutaneous highly purified FSH administration of ovulation induction. Hum Reprod 1994; 9: 1430–6.
Chappel S, Kelton C, Nugent N. Expression of human gonadotropins by recombinant DNA methods. In: Genazzani AR, Petraglia F eds. Proceedings of the 3rd World Congress on Gynaecological Endocrinology. Carnforth: Parthenon Publishing Group, 1992: 179–84.
Olijve W, De Boer W, Mulders JWM et al. Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon). Mol Hum Reprod 1996; 2: 371–82.
Luomaye E, Campbell R, Salat-Baroux J. Human-follicle-stimulating hormone produced by recombinant DNA technology: a review for clinicians. Hum Reprod Update 1995; 1: 188–99.
Rekombinant Human FSH Product Development Group. Recombinant follicle stimulating hormone: development of the first biotechnology product of the treatment of infertility. Hum Reprod Update 1998; 4: 862–81.
Raphael RE. Gonadotropins and combined gonadotropin-releasing hormone agonist-gonadotropins protocols in a randomized prospective study. Fertil Steril 1991; 55: 574–8.
Letterie GS. Inhibition of gonadotropin surge by a brief mid-cycle regimen of adhinyl estradiol and noredhindrone: possible rule in in vitro fertilization. Gynaecol Endocrinol 2000; 14: 1–4.
Strowitzki T, Kentenich H, Kiesel L, Neulen J, Bilger W. Ovarian stimulation in women undergoing in-vitro fertilization and embryo transfer using recombinant human follicle stimulating hormone (Gonal-F) in non-downregulated cycles. Hum Reprod 1995; 10: 3097–101.
Cees AM, Jansen et al. A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down regulated in vitro fertilization patients. Hum Reprod 1998; 13: 2995–9.
Smitz J, Devroey P et al. Management of failed cycles in an IVF-GIFT programme with the combination of a GnRH analogue and hMG. Hum Reprod 1987; 2: 309–14.
Loumaye E. The control of endogenous secretion of LH by gonadotrophinreleasing hormone agonist during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. Hum Reprod 1990; 5: 357–76.
Houghes EG, Fedorkow DM, Daya S et al. The routine use gonadotrophinereleasing hormone agonist prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992; 58: 888–96.
Meden-Vrtovec H. Indukcija ovulacije. In: Prelevič GM ed. Klinička reproduktivna endokrinologija. 3th ed. Beograd: Nauka, 1996: 409–28.
Olivennes F, Fanchin R, Bouchard P et al. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. Fertil Steril 1994; 62: 468–76.
Lemay A, Maheux R, Faure N et al. Reversible hipogonadism induced by a luteinising hormone releasing hormone (LH-RH) agonist (buserelin) as a new therapeutic approach for entometriosis. Fertil Steril 1984; 41: 863–71.
Reissman T, Felberbaum R, Diedrich K et al. Development and applications of luteinising hormone releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 1995; 10: 1974–81.
Diedrich K, Felderbaum R. New approaches to ovarian stimulation. Hum Reprod 1998; 13: Suppl 3: 1–13.
Tan SL, Kingsland C, Campbell S et al. The long protocole of administration of gonadotrophin-releasing hormone agonist is superior to the short protocole for ovarian stimulation for in vitro fertilization. Fertil Steril 1992; 57: 810–4.
Tapanainen J, Hovatta O, Juntunen K et al. Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: A randomized comparative study. Hum Reprod 1993; 8: 2052–5.
FIVNAT 1995 French in-vitro national evaluation. Contracept Fertil Sex 1996; 24: 694–9.
Hughes E, Fedorkow D, Daya S et al. The routine use of GnRHa prior to IVF and GIFT, a meta-analysis of randomized controlled trials. Fertil Steril 1992; 58: 888–96.
Maroulis G, Emery M, Verkauf B et al. Prospective randomized study of human menotropine versus follicular and luteal phase GnRHa/human menotropine stimulation pretocols for IVF. Fertil Steril 1991; 55: 1126–31.
Rutheford A, Subak-Sharp R, Daffson K et al. Improvement of IVF after treatment with buserelin, an agonist of LHRH. Br Med J 1988; 296: 1765–8.
Testard J, Forman J, Belaisch-Allart J et al. Embryo quality and uterine receptivity in IVF cycles with or without GnRHa. Hum Reprod 1989; 4: 198–201.
Elgendy M, Afnan M, Holder R et al. Reducing the dose of gonadotropin releasing hormone agonist on starting ovarian stimulation: effect on ovarian response and IVF outcome. Hum Reprod 1998; 13: 2382–5.
Porter RN, Smith V, Craft IL et al. Induction of ovulation for in vitro fertilization using buserelin and gonadotropins. Lancet 1984; 2: 1284–5.
Akagbosu FT. The use of GnRH agonist and antagonists in infertility. In: Brinsden PR ed. In vitro fertilization and assisted reproduction. 1th ed. New York: The Parthenon Publishing Group, 1999: 83–9.
Filicori M. Polycystic ovary syndrome: abnormalities and management with pulsatile gonadotrophin-releasing hormone and gonadotrophin-releasing hormone analogs. Am J Obstet Gynecol 1990; 163: 1737–42.
Lamberc SWJ, Timmers JM, Osterom R et al. Testosterone secretion by cultured Arrphenoblastoma cells: Suppression by luteinising hormone agonist. J Clin Endocrinol Metab 1982; 54: 450–0.
Damario MA, Barmat L, Liu CH, Davis OK et al. Dual suppression with oral contraceptives and gonadotropin releasing hormone agonists improves invitro fertilization outcome in high responder patients. Hum Reprod 1997; 12: 2359–65.
Smitz J, Ron-El R, Tarlatzis BC. The use of gonadotrophin-releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: experience from three centres. Hum Reprod 1992; 7: Suppl 1: 49–66.
Asta Medica. Cetrorelix, a new millennium in the treatment with IVF. File. Diemen: Asta Medica, 1999.
Bouchard P, Fauser BCJM. Gonadotropin-releasing hormone antagonist: new tools vs. old habits. Fertil Steril 2000; 73: 18–20.
Asta Medica. Cetrotide®. Product Monograph. Asta Medica, 1999.
Diedrich K. World-wide experience with Cetrotide® in the multiple dosing regimen. In: Ferti Magazine, Special ESHRE 2000 Reports.
http://www.ferti.net/med/fertimagazine/congressreport/eshre2000-24.asp
Olivennes F, Belaisch-Allart J, Emperaire JC et al. Prospective, randomized, controlled study of in vitro fertilisation-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000; 73: 314–20.
Albano C, Felberbaum RE, Smitz J et al. Ovarian stimulation with HMG: results of a prospective randomised phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod 2000; 15: 526–31.
The European Orgalutran® Study Group, Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000; 15: 1490–8.
Diedrich K, Felberbaum R. LHRH-antagonists: Where are the advantages in ART? In: Cetrotide. A new concept is born in the control of ovarian stimulation. Tours: ESHRE ’99, ASTA Medica Symposium, 1999: 2–5.
Olivennes F, Fanchin R, Rongieres-Bertrand C, Bouchard P, Frydman R. LHRH-antagonist (Cetrorelix) in single dose applications. In: Cetrotide. A new concept is born in the control of ovarian stimulation. ASTA Medica Symposium. Tours: ESHRE ’99, 1999: 6–7.
Riethmüller-Winzen H, Prothmann A, Peukert M, Engel J. Cetrotide® (Cetrorelix) pregnancy rates and safety aspects. In: Cetrotide. A new concept is born in the control of ovarian stimulation. ASTA Medica Symposium. Tours: ESHRE ’99, 1999: 8–9.
De Jong D, Macklon NS, Mannaerts BMJL, Coelingh Bennink HJT, Fauser BCJM. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilisation. Hum Reprod 1998; 13: 573–5.
Medved R, Meden-Vrtovec H. Primerjava uporabe GnRH antagonistov in GnRH agonistov v postopku zunajtelesne oploditve – preliminarni rezultati. In: Kralj B, Denona V eds. Zbornik 2. kongresa ginekologov in porodničarjev Slovenije z mednarodno udeležbo; 2000, Nov. 19–22; Portorož, Slovenija. Ljubljana: Združenje ginekologov in porodničarjev Slovenije; 2000: 236–6.
Dossier FIVNAT 96. French National Registry 1996.
Dossier FIVNAT 99. French National Registry 1999.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
